Kartesia supports acquisition of Optegra by MidEuropa

Kartesia, the European specialist provider of capital solutions for small and mid-sized companies, is pleased to announce that it has provided a financing package to support MidEuropa Partners (“MidEuropa”) in its acquisition of a majority stake in Optegra Eye Health Care (“Optegra”).

Optegra is a leading European ophthalmology platform operating in Poland, Czech Republic, Slovakia and the UK. The Company is led by an experienced management team who are reinvesting alongside MidEuropa and the current sponsor, H2 Equity Partners (“H2”). Kartesia first invested in the business in 2020 alongside H2, helping to deliver Optegra’s ambitious growth strategy and ensure continued provision of high-quality care to its patients.

Optegra offers a wide range of procedures including cataract, AMD, and vision correction for both public and private patients. The Company operates 29 highly integrated state-of-the art facilities and performs over 100k surgical procedures per year with a focus on industry-leading clinical outcomes and outstanding patient experience.

The capital for this investment is provided by Kartesia Senior Opportunities (“KSO”) Funds I & II and the deal team at Kartesia included Nick Holman, Sebastian Afflerbach, and Serafina Di Felice.

Nick Holman, Director at Kartesia, commented: “We are delighted to continue our relationship with Optegra, which has established itself as one of the leading providers of ophthalmologic care in Europe. Since we first invested in the business in 2020 alongside H2, the Company has grown significantly and with the support of new shareholders MidEuropa and a fully underwritten financing solution from Kartesia, it is well-positioned to expand its position in the European healthcare market.”